S&P 500 7,811.54 +0.59%Nasdaq 27,366.17 +0.64%Dow 51,654.95 +0.83%Russell 2000 2,806.98 +0.46%as of 2026-10-09 close
▚ The MicroCap Herald
Micro-cap and nano-cap intelligence, before the crowd
Market Pulse

The Russell 2000 Was the Only Major Index to Fall in the Week to Oct. 9, Down 0.91%, While the Micro-Cap ETF Lost 1.97% and Three IPOs Priced, One of Them a SPAC

TheStreet's 4 p.m. wrap put the Russell 2000 at 2,808.57 on Friday; Nasdaq's historical table shows the iShares Micro-Cap ETF closing at 183.00, from 186.68 a week earlier. Renaissance Capital counted two biotech IPOs and one blank-check pricing, plus ten new filings, in the week of Oct. 5.
Illustrative photograph: a printed financial chart and market data.

Small stocks spent the week to Friday, Oct. 9 going the other way from large ones. TheStreet's market wrap, time-stamped 4:00 p.m. Eastern on Oct. 9, recorded the Russell 2000 at 2,808.57, up 14.45 points or 0.52% on the day (the Oct. 9 index level here is TheStreet's print; FTSE Russell's official close was not available on its public pages, and other feeds may show a level a point or two different), while the S&P 500 closed at 7,811.51 (+0.59%), the Dow at 51,655.01 (+0.83%) and the Nasdaq Composite at 27,366.17 (+0.64%). On the week, the same wrap said, 'The Russell 2000 (-0.91%) was the only major index to decline,' against gains of 1.15% for the Dow, 0.95% for the S&P 500 and 0.19% for the Nasdaq.

The path within the week is visible in Yahoo Finance's historical table for the index: 2,832.90 on Friday, Oct. 2; 2,847.14 on Monday, Oct. 5; 2,830.30 on Tuesday; 2,793.20 on Wednesday, Oct. 7, the week's low close; and 2,794.13 on Thursday. Friday's rebound was not enough to recover Wednesday's drop. (Markets are closed Saturday; there is no Oct. 10 price action to report.)

Further down the capitalisation ladder the week was worse. The iShares Micro-Cap ETF (IWC), which tracks the Russell Microcap Index, closed at 183.00 on Oct. 9 against 186.68 on Oct. 2, according to Nasdaq's historical table for the fund — a 1.97% weekly decline by our arithmetic, roughly double the Russell 2000's. The fund's closes were 187.32 on Oct. 5, 185.39 on Oct. 6, 183.36 on Oct. 7 and 182.79 on Oct. 8, so unlike the Russell 2000 it kept falling into Thursday. The iShares Russell 2000 ETF (IWM) closed at 278.94 from 281.52, down 0.92% by our arithmetic, in line with the index.

A fortnight back the picture is similar. IWC closed at 187.77 on Sept. 25, so the two-week decline runs to about 2.5% (our arithmetic). That makes two consecutive down weeks for the fund on these closes.

The new-issue count for the week came from Renaissance Capital's weekly recap, printed Oct. 9: 'Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company.' Its pricing table lists three deals: TRex Bio (TRXB), which 'priced at the low end to raise $117 million at a $422 million market cap' and 'finished flat'; Pine Tree Acquisition (PAXGU), a $100 million blank-check company that the recap's table shows pricing in line with its midpoint with a 0% first-day return; and Retension Pharmaceuticals (RTSN), which 'upsized and priced at the midpoint to raise $45 million at a $114 million market cap' and 'finished down 12%.' The recap counts '10 Filings During the Week of October 5th, 2026.'

Nasdaq's own IPO calendar for October shows one pricing in the Oct. 5-9 window: Pine Tree Acquisition Corp., 10,000,000 units at $10.00 for $100,000,000 on the Nasdaq Global Market, priced Oct. 6. The calendar's other October pricings were Chilwa Minerals Ltd, 625,000 shares at $5.60 for $3,500,000 on the Nasdaq Capital Market on Oct. 1, and, on the NYSE side of the same calendar, Southport Acquisition Corp. II at $200,000,000 the same day. Chilwa's was the smallest of the three October pricings and the only one on the Capital Market.

We ran our own check against EDGAR. A full-text search of Form 424B4 final prospectuses filed Oct. 5 through Oct. 9 containing the phrase 'initial public offering' returned four filers: Pine Tree Acquisition Corp. (Oct. 6), Basel Medical Group Ltd (Oct. 8), and TRex Bio, Inc. and Retension Pharmaceuticals, Inc. (both Oct. 9). Basel Medical Group already trades as BMGL, so its prospectus is a follow-on rather than a debut; that leaves three true IPO prospectuses, matching Renaissance's count. This is our tally, not a published one.

The micro-cap end of the pipeline is where the week's more telling items sit. Renaissance reported on Oct. 8 that Australian metal-powder producer Amaero 'revived its US IPO plans on Thursday with a new SEC filing disclosing a lower proposed share offering,' and now plans to 'raise $20 million by offering 3.9 million shares at an assumed offer price of $5.15,' down from an earlier $53 million (7.5 million shares at $7.06) — a cut of about 60%, with a fully diluted market value of $143 million, 35% lower than the previous terms. The company, listed on the ASX as 3DA, proposes the Nasdaq ticker AMRO; Renaissance says 'IPO timing has not been determined.'

Two smaller filings and one withdrawal round out the small-deal ledger. Renaissance's headlines record Patriot Mobile filing for a $10 million IPO on Oct. 9 and Malaysia-based electrical distributor LPC filing for a $19 million US IPO on Oct. 2. On Oct. 7, Canadian push-to-talk device maker Siyata PTT withdrew its plan for a direct listing on Nasdaq; Nasdaq's calendar lists the withdrawn deal at 6,112,327 shares with no dollar value.

Blank-check supply kept coming. Beyond Pine Tree's pricing, Renaissance logged SPAC filings or term changes from Tang Capital Acquisition ($75 million, filed Oct. 6), Arca Nova Acquisition ($100 million, Oct. 2), Allarity Acquisition (units cut 20% ahead of an $80 million deal, Oct. 6) and Calm Seas Acquisition (units cut 25% ahead of a $200 million deal, Oct. 8). Nasdaq's filed list for October also shows New Iceland Arctic Acquisition at $115 million after an earlier $143.75 million version appears under withdrawn.

For scale against the broader IPO market, Renaissance's recap states that 'As of 10/8/2026, the Renaissance IPO Index was up 16.3% year-to-date, while the S&P 500 was up 14.4%.' Two of the fortnight's more striking single-session micro-cap moves, both covered separately and both from Nasdaq's historical tables, were Alpha Modus Holdings, which closed at $3.49 on Oct. 2 from $1.17, and BIO-key International, whose $3.12 close on Sept. 29 had unwound to $1.67 by Friday.

One more name moved on Friday itself. Veea Inc. (Nasdaq: VEEA) closed at $5.70 on Oct. 9 from $3.87 on Oct. 8, on 83,591,400 shares, per Nasdaq's historical table, its third session above 60 million shares in seven. The company's 8-Ks that week disclosed $1.65 million of 10% demand notes from NLabs Inc., 'a principal stockholder of the Company and an affiliate of the Company's Chief Executive Officer,' a director's resignation from the board while remaining chief revenue officer, and committee appointments. None of the filings addresses the trading.

What comes next: Renaissance's week-ahead note, also dated Oct. 9, says 'biotechs continue to tap the public market, with two more on the calendar for the week ahead' — Iambic Therapeutics (IAM), $150 million at $15 to $17, and City Therapeutics (CTY), $175 million at $17 to $19 for a market cap it puts at $1.0 billion. Neither is a micro-cap. Whether Amaero, Patriot Mobile or LPC set a date is not yet known, and the Russell Microcap Index's own official weekly close was not available from FTSE Russell's public pages at the time of writing, which is why the ETF stands in for it here.

This article is for general information only and is not investment advice. Figures are as reported by the cited sources at time of writing.

Related coverage

Illustrative photograph: US banknotes and coins.
Market Pulse

Eleven Small-Company Reverse Splits Took Effect Between Sept. 28 and Oct. 8, From 1-for-10 to 5,000-for-1. Under Nasdaq Rule 5810(c)(3)(A)(iv), Each of the Seven Nasdaq Names on the List Has No Cure Period if Its Bid Fails the $1 Test Within a Year.

8-Ks on EDGAR show seven Nasdaq, two NYSE American and two OTC consolidations among the micro- and small-caps we tracked, with two more Nasdaq splits set for Oct. 12; the list is not exhaustive. Vivakor's 1-for-15 follows a 1-for-20 in July, a cumulative 300-to-1 by our arithmetic, above the rule's 250-to-1 two-year threshold.

Wesley Stroud · October 10, 2026
Illustrative photograph: stock-market trading screens showing price charts.
Market Pulse

bioAffinity clears two Nasdaq deficiencies and its hearing is cancelled, leaving about 592,373 shares outstanding

A Nasdaq letter dated Sept. 8 confirmed compliance with both the minimum bid price rule and the rights-and-warrants rule, cancelling a Hearings Panel appearance the company had been pushed into because a reverse split within the prior year disqualified it from any cure period. Two splits in eleven months compound to 450-to-1, above the 250-to-1, two-year threshold written into the same rule.

Wesley Stroud · September 10, 2026
Illustrative photograph: stock-market trading screens showing price charts.
Market Pulse

Two Nasdaq Companies Got Second Bid-Price Windows Running to March 1, 2027. A Third Closed Its Case Today

Alpha Compute and DeFi Technologies each disclosed an additional 180-day period this week, both ending on the same date despite deficiency notices issued three days apart in March. CLPS said on Sept. 4 that it cleared the $1.00 threshold for ten sessions running to Sept. 2.

Wesley Stroud · September 4, 2026